MARKET

IMGN

IMGN

ImmunoGen
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.810
-0.260
-6.39%
After Hours: 3.850 +0.04 +1.05% 16:46 09/21 EDT
OPEN
3.940
PREV CLOSE
4.070
HIGH
3.975
LOW
3.800
VOLUME
2.42M
TURNOVER
--
52 WEEK HIGH
7.07
52 WEEK LOW
1.950
MARKET CAP
665.01M
P/E (TTM)
-8.9081
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
ImmunoGen (IMGN) Investor Presentation - Slideshow
The following slide deck was published by ImmunoGen, Inc. in conjunction with this event.
Seekingalpha · 4d ago
ImmunoGen's mirvetuximab shows treatment benefit in FRα-positive ovarian cancer
ImmunoGen (IMGN) announces final data from the FORWARD II triplet cohort evaluating mirvetuximab soravtansine in combination with carboplatin and Avastin (bevacizumab) in patients with folate receptor alpha (FRα)-positive recurrent, platinum-sensitive
Seekingalpha · 4d ago
ImmunoGen Presents Final Data From Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination With Carboplatin and Avastin® at ESMO
ImmunoGen Presents Final Data from Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab in Combination with Carboplatin and Avastin® at ESMO
Business Wire · 4d ago
What Can We Conclude About ImmunoGen's (NASDAQ:IMGN) CEO Pay?
This article will reflect on the compensation paid to Mark Enyedy who has served as CEO of ImmunoGen, Inc...
Simply Wall St. · 09/14 17:20
The Week Ahead In Biotech: Decision Day For Bausch Health, IPO Flow Resumes, Oncology Conference
Biotech stocks continued to remain under pressure in the week ended Sept. 11, swayed by the volatility that was evident in the broader market.
Benzinga · 09/13 13:49
ImmunoGen Announces Webcast of Presentation at Upcoming H.C. Wainwright Virtual Global Investment Conference
ImmunoGen Announces Webcast of Presentation at Upcoming H.C. Wainwright Virtual Global Investment Conference
Business Wire · 09/02 21:30
Why Is ImmunoGen (IMGN) Down 14.4% Since Last Earnings Report?
ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 08/30 16:30
ImmunoGen: Turning Around In A Coronavirus Environment
ImmunoGen is a turnaround stock that has tremendous potential. After temporary regulatory and clinical setbacks, the company is on a vigorous campaign for a change.
Seeking Alpha - Article · 08/25 18:03
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IMGN stock price target is 6.96 with a high estimate of 12.00 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 293
Institutional Holdings: 148.21M
% Owned: 84.91%
Shares Outstanding: 174.54M
TypeInstitutionsShares
Increased
66
17.00M
New
56
-5.31M
Decreased
51
10.52M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.94%
Pharmaceuticals & Medical Research
-2.24%
Key Executives
Chairman/Director
Stephen McCluski
President/Chief Executive Officer/Director
Mark Enyedy
Chief Financial Officer/Senior Vice President
Susan Altschuller
Senior Vice President
Anna Berkenblit
Senior Vice President
Stacy Coen
Senior Vice President
Theresa Wingrove
Vice President
Thomas Ryll
Independent Director
Stuart Arbuckle
Independent Director
Mark Goldberg
Independent Director
Dean Mitchell
Independent Director
Kristine Peterson
Independent Director
Richard Wallace
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More

Analyst Price Target

The average IMGN stock price target is 6.96 with a high estimate of 12.00 and a low estimate of 4.000.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About IMGN
ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra), which is in a Phase III registrational trial called FORWARD I. Its FORWARD II trial consists of cohorts assessing Mirvetuximab soravtansine in combination with Avastin (bevacizumab), Keytruda (pembrolizumab) and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4, as well as deoxyribonucleic acid (DNA)-alkylating agents called IGNs.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of ImmunoGen, Inc. stock information, including NASDAQ:IMGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMGN stock methods without spending real money on the virtual paper trading platform.